How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,308 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Influence of Carob and Probiotics on Acute Diarrhea in Children

and Probiotics on Acute Diarrhea in Children The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01501305 Recruitment Status : Unknown Verified December 2011 by Hillel Yaffe Medical Center. Recruitment status was: Not yet recruiting First Posted : December 29, 2011 Last Update Posted : December 29, 2011 Sponsor (...) : Hillel Yaffe Medical Center Information provided by (Responsible Party): Hillel Yaffe Medical Center Study Details Study Description Go to Brief Summary: Comparison of Carob powder with probiotics vs oral hydration solution in diarrhea treatment in children. Condition or disease Intervention/treatment Phase Diarrhea Dietary Supplement: Mineral solution Dietary Supplement: Carob powder with probiotics Phase 1 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional

2011 Clinical Trials

162. A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01494233

2011 Clinical Trials

163. The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers

will be allowed during the study Receipt of influenza vaccination will be allowed prior, during, and/or after the study Use of topical medications that are not significantly absorbed systemically will be allowed if approved by the Principal Investigator Inability to obtain venous access for sample collection. Inability to swallow whole capsules and/or tablets. Positive serum or urine pregnancy test or breastfeeding female. The presence of persistent diarrhea or malabsorption that could interferewith (...) The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2013 Clinical Trials

164. Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease

have shown that sexual function is impaired in patients with Crohn's disease. It is likely that both the symptoms related to the disease, medications used to treat the disease, and surgery all impair sexual function in a variety of ways. For example, body image may be impaired, patients may be worried about bowel incontinence or unpleasant odors associated with diarrhea, patients may have significant pelvic pain secondary to perianal fistulas, or they may have painful intercourse from adjacent (...) : Vanderbilt University Milton S. Hershey Medical Center Mercy Medical Center Information provided by (Responsible Party): Raymond Cross, University of Maryland Study Details Study Description Go to Brief Summary: Crohn's disease is a chronic inflammatory condition of the intestines that causes abdominal pain, diarrhea, tunnels around the anus (fistulas), and extraintestinal symptoms. Effective medical treatments exist to treat the disease; however they can have significant side effects. Previous studies

2015 Clinical Trials

165. Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial

decline. The primary composite endpoint is combined adverse outcome within 30 days defined as (a) all-cause mortality, (b) admission to the intensive care unit from the medical ward, (c) major complications, (d) unplanned hospital readmissions and (d) decline in functional outcome from admission to day 30 assessed by Barthel`s index (-10%). Secondary endpoints include (a) each single component of the primary endpoint (b) short-term nutritional and functional outcomes from inclusion to day 10 (...) of baseline creatinine or new requirement of dialysis), gastro-intestinal hemorrhage or intestinal perforation assessed by medical chart review and telephone interview decline in functional status of 10% or more from admission to day 30 measured by the Barthel`s index assessed by patient interview on admission and after 30 days Secondary Outcome Measures : Weight change [ Time Frame: measured at day 30 by telephone interview ] change in weight and BMI from inclusion to day 30 by patient interview

2015 Clinical Trials

166. Determining the Responsiveness of Depression Questionnaires and Optimal Treatment Duration for Antidepressant Medications

Determining the Responsiveness of Depression Questionnaires and Optimal Treatment Duration for Antidepressant Medications Evidence-based Synthesis Program Department of Veterans Affairs Health Services Research & Development Service Evidence-based Synthesis Program Evidence Synthesis for Determining the Responsiveness of Depression Questionnaires and Optimal Treatment Duration for Antidepressant Medications Department of Veterans Affairs Health Services Research & Development Service October (...) 2009 Investigators: John W. Williams Jr., MD, MHS Professor of Medicine and Psychiatry, Durham VA Medical Center and Duke University Director, Evidence-Based Practice Center Durham, NC Monica Nora Slubicki, MD Resident in Psychiatry, VA Administrative Chief Resident 2009-2010, Duke University Medical Center Durham, NC Damon S. Tweedy, MD Medical Director, Primary-Care Mental Health Integration, Durham VA Medical Center Consulting Associate, Duke University Medical Center Durham, NC Prepared

2009 Veterans Affairs Evidence-based Synthesis Program Reports

167. Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION)

with Duodenal Switch Active Comparator: Control the best medical management of their diabetes, non-surgical group Other: Medical management Outcome Measures Go to Primary Outcome Measures : Type 2 diabetes remission rate [ Time Frame: from baseline up to 60 months ] percent of patient achieving type 2 diabetes remission in each groups Secondary Outcome Measures : Change in microalbuminuria [ Time Frame: from baseline up to 60 months ] Normalisation of A/C ratio after surgery Change in retinopathy [ Time (...) Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION) Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2015 Clinical Trials

168. Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation

(suction curettage or D&C) for any reason Secondary Outcome Measures : Proportion of Individual Side Effects Experienced by Participants [ Time Frame: 7-14 days ] Side effects include diarrhea, nausea, vomiting, fever, chills, headaches, dizziness and/or weakness experienced by participants Proportion of Women Who Determine Method Acceptable [ Time Frame: 7-14 days ] overall acceptability, time to complete abortion, bleeding, side effects, pain Proportion of Providers Who Determine Method Acceptable (...) Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2014 Clinical Trials

169. The Effectiveness and Cost-effectiveness of Medical Advice Given by Telephone for Patients Calling for Primary Care

by a general practitioner or in an emergency department, during out-of-hours periods Secondary Outcome Measures : Cost effectiveness [ Time Frame: at 15 days ] Cost effectiveness based on the economic analysis in each arm (sick leaves, hospitalization, EMS or firemen use...) Care Mobile Units use [ Time Frame: at 15 days ] Emergency Medical Service use [ Time Frame: at 15 days ] Firemen use [ Time Frame: at 15 days ] Number of fireman use Recall at dispatching centre [ Time Frame: at 15 days ] Number (...) The Effectiveness and Cost-effectiveness of Medical Advice Given by Telephone for Patients Calling for Primary Care The Effectiveness and Cost-effectiveness of Medical Advice Given by Telephone for Patients Calling for Primary Care - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2014 Clinical Trials

170. Ussing Experiments to Evaluate the Role of Medication-induced Microscopic Colitis

Ussing Experiments to Evaluate the Role of Medication-induced Microscopic Colitis Ussing Experiments to Evaluate the Role of Medication-induced Microscopic Colitis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Ussing Experiments to Evaluate the Role of Medication-induced Microscopic Colitis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02303132 Recruitment Status : Completed First Posted : November 27, 2014 Last Update Posted : July 19, 2016 Sponsor: Maastricht University Medical Center

2014 Clinical Trials

171. Medical Home Care for Hematopoietic Stem Cell Transplantation Phase 2

disease physicians, gastroenterologists, psychiatrists, nutritionists, pharmacists, social workers, financial coordinators, etc.; managing medication regimens to prevent infections, GVHD, and other complications (not to mention avoiding drug and food interactions); adjusting to multiple side effects including fatigue, weakness, anorexia, nausea, vomiting, diarrhea, rashes, pain, anxiety, stress, organ failure, etc.; the sheer amount of time required for healthcare visits, lab draws, waiting (...) Medical Home Care for Hematopoietic Stem Cell Transplantation Phase 2 Medical Home Care for Hematopoietic Stem Cell Transplantation Phase 2 - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Medical Home Care

2014 Clinical Trials

172. Medical Treatment of Stroke (Diagnosis)

stroke prevention may include the use of antihypertensive medications, anticoagulants, platelet antiaggregants, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), smoking cessation, dietary intervention, weight loss, and exercise. Modifiable risk factors include the following: Hypertension Air pollution Cigarette smoking Diabetes Dyslipidemia Atrial fibrillation Sickle cell disease Postmenopausal HRT Depression Diet and activity Weight and body fat Secondary Prevention (...) of Stroke Secondary prevention can be summarized by the mnemonic A, B, C, D, E, as follows: A - Antiaggregants (aspirin, clopidogrel, extended-release dipyridamole, ticlopidine) and anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban, warfarin) B - Blood pressure–lowering medications C - Cessation of cigarette smoking, cholesterol-lowering medications, carotid revascularization D - Diet E – Exercise Smoking cessation, blood pressure control, diabetes control, a low-fat diet (eg, Dietary

2014 eMedicine.com

173. Medical Treatment of Stroke (Overview)

stroke prevention may include the use of antihypertensive medications, anticoagulants, platelet antiaggregants, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), smoking cessation, dietary intervention, weight loss, and exercise. Modifiable risk factors include the following: Hypertension Air pollution Cigarette smoking Diabetes Dyslipidemia Atrial fibrillation Sickle cell disease Postmenopausal HRT Depression Diet and activity Weight and body fat Secondary Prevention (...) of Stroke Secondary prevention can be summarized by the mnemonic A, B, C, D, E, as follows: A - Antiaggregants (aspirin, clopidogrel, extended-release dipyridamole, ticlopidine) and anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban, warfarin) B - Blood pressure–lowering medications C - Cessation of cigarette smoking, cholesterol-lowering medications, carotid revascularization D - Diet E – Exercise Smoking cessation, blood pressure control, diabetes control, a low-fat diet (eg, Dietary

2014 eMedicine.com

174. Medical Treatment of Stroke (Treatment)

stroke prevention may include the use of antihypertensive medications, anticoagulants, platelet antiaggregants, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), smoking cessation, dietary intervention, weight loss, and exercise. Modifiable risk factors include the following: Hypertension Air pollution Cigarette smoking Diabetes Dyslipidemia Atrial fibrillation Sickle cell disease Postmenopausal HRT Depression Diet and activity Weight and body fat Secondary Prevention (...) of Stroke Secondary prevention can be summarized by the mnemonic A, B, C, D, E, as follows: A - Antiaggregants (aspirin, clopidogrel, extended-release dipyridamole, ticlopidine) and anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban, warfarin) B - Blood pressure–lowering medications C - Cessation of cigarette smoking, cholesterol-lowering medications, carotid revascularization D - Diet E – Exercise Smoking cessation, blood pressure control, diabetes control, a low-fat diet (eg, Dietary

2014 eMedicine.com

175. Medical Treatment of Stroke (Follow-up)

stroke prevention may include the use of antihypertensive medications, anticoagulants, platelet antiaggregants, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), smoking cessation, dietary intervention, weight loss, and exercise. Modifiable risk factors include the following: Hypertension Air pollution Cigarette smoking Diabetes Dyslipidemia Atrial fibrillation Sickle cell disease Postmenopausal HRT Depression Diet and activity Weight and body fat Secondary Prevention (...) of Stroke Secondary prevention can be summarized by the mnemonic A, B, C, D, E, as follows: A - Antiaggregants (aspirin, clopidogrel, extended-release dipyridamole, ticlopidine) and anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban, warfarin) B - Blood pressure–lowering medications C - Cessation of cigarette smoking, cholesterol-lowering medications, carotid revascularization D - Diet E – Exercise Smoking cessation, blood pressure control, diabetes control, a low-fat diet (eg, Dietary

2014 eMedicine.com

176. Misoprostol for Secondary Prevention of Postpartum Hemorrhage at the Community Level in India

Health Projects Collaborators: Sri B. M. Patil Medical College, Bijapur, Karnataka, India Jawaharlal Nehru Medical College University of Illinois at Chicago University of California, San Francisco Information provided by (Responsible Party): Gynuity Health Projects Study Details Study Description Go to Brief Summary: This study compares two community-level strategies: selective administration of 800 mcg sublingual misoprostol to women at 350 mL blood loss for secondary prevention of postpartum (...) Misoprostol for Secondary Prevention of Postpartum Hemorrhage at the Community Level in India Misoprostol for Secondary Prevention of Postpartum Hemorrhage at the Community Level in India - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2011 Clinical Trials

177. Brilinta (ticagrelor) Tablets - medical review

Brilinta (ticagrelor) Tablets - medical review CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022433Orig1s000 MEDICAL REVIEW(S) DIVISION OF CARDIOVASCULAR AND RENAL PRODUCTS Complete Response Review Addendum Sponsor Safety Reporting Submissions: NDA 22-433 and IND 65,808 SD 632 Drug: ticagrelor (Brilinta™) Indication: reduce the rate of thrombotic events in patients with acute coronary syndromes (ACS) Sponsor: AstraZeneca Review date: June 8, 2011 Reviewer: Thomas A. Marciniak, M.D (...) . Medical Team Leader On April 20, 2011, we met with AstraZeneca (AZ) staff to discuss progress on the reviews of the complete response for NDA 22-433. Because my review and that of the IND reviewer, Dr. Martin Rose, had suggested significant problems with AZ’s handling of serious adverse events (SAEs), I added to the end of the agenda a discussion of these problems. The minutes for the meeting filed on May 19, 2011, summarize that discussion as follows: “There was some discussion regarding

2011 FDA - Drug Approval Package

178. Chronic obstruction of the antrum of the stomach by a mucosal diaphragm, with malnutrition, impairment of growth and secondary small intestine damage. (PubMed)

Chronic obstruction of the antrum of the stomach by a mucosal diaphragm, with malnutrition, impairment of growth and secondary small intestine damage. 5150064 1972 08 11 2018 11 13 0041-6193 41 1 1971 Winter The Ulster medical journal Ulster Med J Chronic obstruction of the antrum of the stomach by a mucosal diaphragm, with malnutrition, impairment of growth and secondary small intestine damage. 39-44 Irwin J W JW Logan J S JS Porter D C DC eng Journal Article Northern Ireland Ulster Med J (...) 0417367 0041-6193 IM Adolescent Adult Diarrhea etiology Female Growth Disorders etiology Humans Intestinal Diseases etiology Intestine, Small Nutrition Disorders etiology Stomach Diseases complications 1971 1 1 1971 1 1 0 1 1971 1 1 0 0 ppublish 5150064 PMC2385293 Surg Gynecol Obstet. 1968 Nov;127(5):999-1004 5681358 Ulster Med J. 1971;40(2):151-7 5150057 Surgery. 1966 May;59(5):681-4 5931478 Br J Surg. 1949 Oct;37(146):244-6, illust 15395097 Gastroenterology. 1967 Jun;52(6):1003-8 6026482 Br J Surg

Full Text available with Trip Pro

1971 The Ulster medical journal

179. Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit

Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02025855 Recruitment Status : Unknown Verified January 2014 by Thomas Smoot, PharmD, BCPS, Henry

2013 Clinical Trials

180. MEdical Versus SUrgical Treatments of Rectal Endometriosis

MEdical Versus SUrgical Treatments of Rectal Endometriosis MEdical Versus SUrgical Treatments of Rectal Endometriosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. MEdical Versus SUrgical Treatments (...) of the rectum and not having pregnancy intention. The main outcome concerns the quality of digestive function 24 after the onset of the treatment, assessed using a composite variable: patient considering that digestive function is normal AND the Knowles-Eccersley-Scott-Symptom Questionnaire (KESS score) <7 AND the Gastrointestinal Quality of Life Index (GIQLI) score >100. Secondary outcomes are: presence of severe constipation, increased frequency of daily bowel movements, anal incontinence, postoperative

2013 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>